Warning: session_start(): open(/opt/alt/php72/var/lib/php/session/sess_684509ce4ed7d7cb3e8c7029d8474821, O_RDWR) failed: Disk quota exceeded (122) in /home/shweuqjw/awajludhianaki.org/wp-content/plugins/jnews-social-login/class.jnews-social-login.php on line 83

Warning: session_start(): Failed to read session data: files (path: /opt/alt/php72/var/lib/php/session) in /home/shweuqjw/awajludhianaki.org/wp-content/plugins/jnews-social-login/class.jnews-social-login.php on line 83
Don't use Gilead's Remdesivir in hospitalised COVID-19 patients: WHO | World News - Awaj Ludhiana Ki
Friday, June 13, 2025
  • Login
  • Home
  • National
  • International
  • Movies
  • Technology
  • Business
  • Fitness
  • Lifestyle
  • Punjab
  • Contact us
No Result
View All Result
No Result
View All Result
Home International

Don’t use Gilead’s Remdesivir in hospitalised COVID-19 patients: WHO | World News

by author
November 20, 2020
in International
0
Don’t use Gilead’s Remdesivir in hospitalised COVID-19 patients: WHO | World News
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter


LONDON: Gilead`s Remdesivir should not be used for patients hospitalised with COVID-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said on Friday. “The … panel found a lack of evidence that Remdesivir improved outcomes that matter to patients,” the guideline said.

“Especially given the costs and resource implications associated with Remdesivir… the panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data,” it added. The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.

The antiviral, known by the brand name Veklury, is one of only two medicines currently authorised to treat COVID-19 patients across the world. But a large WHO-led trial known as the Solidarity Trial showed last month that it had little or no effect on 28-day mortality or length of hospital stays for COVID-19 patients.

The medication was one of the drugs used to treat U.S. President Donald Trump`s coronavirus infection and had been shown in previous studies to have cut time to recovery. It is authorised or approved for use as a COVID-19 treatment in more than 50 countries. Gilead has questioned the Solidarity Trial`s results and said in a statement on Friday it was “disappointed” at the new WHO guideline.

“Veklury is recognised as a standard of care for the treatment of hospitalised patients with COVID-19 in guidelines from numerous credible national organisations,” it said. The WHO advice raises questions about whether the European Union will need the 500,000 courses of the antiviral, worth 1 billion euros ($1.2 billion), it ordered last month.

The European Commission said on Friday it had taken note of the WHO updated guideline on Remdesivir but that “at the moment, there are no changes” to its authorisation for the drug. It said the region`s drugs regulator, the European Medicines Agency, had requested the full data from the Solidarity Trial and “will assess the evidence … together with other available data, to see if any changes are needed”.

Italy`s drugs regulator, AIFA, said it had been “stressing for weeks the modest effectiveness of Remdesivir”. “In practice, we have been saying for some time that it is not of use for much,” a spokeswoman said.

NO MEANINGFUL EFFECT

The WHO`s Guideline Development Group (GDG) panel said its recommendation was based on an evidence review that included data from four international randomised trials involving more than 7,000 patients hospitalised with COVID-19. After reviewing the evidence, the panel said it concluded that Remdesivir, which has to be given intravenously and is therefore costly and complex to administer, has no meaningful effect on death rates or other important outcomes for patients.

Peter Horby, a professor of emerging infectious diseases at Britain`s Oxford University, said the WHO`s new advice should prompt “a rethink about the place of Remdesivir in COVID-19”. “Remdesivir is an expensive drug that must be given intravenously for five to 10 days, so this recommendation will save money and other healthcare resources,” he said.

U.S. infectious disease doctors said they would continue to use the drug because a double-blind, placebo-controlled U.S. study showed it decreased the length of hospitalization for some COVID-19 patients. “My perspective is, and our institution`s perspective is that this is still a useful drug. It`s not as useful as we`d like it to be,” Dr Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital and Harvard Medical School, said.

Dr Helen Boucher, chief of geographic medicine and infectious diseases at Tufts Medical Center in Boston, said she was taking into consideration that the Solidarity trial was an open-label study – meaning doctors and patients were aware that the drug was given – and not a double-blind, placebo-controlled study. Placebo-controlled studies are generally considered more scientifically rigorous.

Live TV

The recommendation, which is not binding, is part of the WHO`s so-called “living guidelines” project, designed to offer ongoing guidance for doctors. The panel added that it supported continued enrolment into clinical trials evaluating Remdesivir in patients with COVID-19, which it said should “provide higher certainty of the evidence for specific groups of patients”. 





Source link

Related posts

Nuclear Sites Bombed, IRGC Chief And Top Nuke Scientist Killed In Israeli Strikes On Iran – Details | World News

Nuclear Sites Bombed, IRGC Chief And Top Nuke Scientist Killed In Israeli Strikes On Iran – Details | World News

June 13, 2025
Inevitable War? Israel Has Hit Iran, But What Tehran Knows May Change Everything | World News

Inevitable War? Israel Has Hit Iran, But What Tehran Knows May Change Everything | World News

June 13, 2025
Previous Post

Post-Covid reforms to aid India’s medium-term growth: Fitch

Next Post

DNA Exclusive: Lack of commitment and systemic apathy increased dangers of COVID-19 pandemic | India News

Related Posts

Nuclear Sites Bombed, IRGC Chief And Top Nuke Scientist Killed In Israeli Strikes On Iran – Details | World News
International

Nuclear Sites Bombed, IRGC Chief And Top Nuke Scientist Killed In Israeli Strikes On Iran – Details | World News

June 13, 2025
Inevitable War? Israel Has Hit Iran, But What Tehran Knows May Change Everything | World News
International

Inevitable War? Israel Has Hit Iran, But What Tehran Knows May Change Everything | World News

June 13, 2025
PM Modi-Carney G7 Meeting Opportunity To Explore Pathways To Reset India-Canada Ties: MEA | India News
International

PM Modi-Carney G7 Meeting Opportunity To Explore Pathways To Reset India-Canada Ties: MEA | India News

June 12, 2025
Who Is Bobby Mukkamala? Indian-Origin Doctor Makes History As AMA President, Credits Parents | World News
International

Who Is Bobby Mukkamala? Indian-Origin Doctor Makes History As AMA President, Credits Parents | World News

June 12, 2025
Inside America’s Long Tieng: The Most Secret Nerve Centre Of A Covert CIA Operation | World News
International

Inside America’s Long Tieng: The Most Secret Nerve Centre Of A Covert CIA Operation | World News

June 11, 2025
Holding Onto Chair: The Many Tactics Of Bangladesh’s Muhammad Yunus | World News
International

Holding Onto Chair: The Many Tactics Of Bangladesh’s Muhammad Yunus | World News

June 11, 2025
Next Post
DNA Exclusive: Lack of commitment and systemic apathy increased dangers of COVID-19 pandemic | India News

DNA Exclusive: Lack of commitment and systemic apathy increased dangers of COVID-19 pandemic | India News

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

The Last Citadel: Taliban take control of Kabul airport, do a symbolic march across runway | World News

The Last Citadel: Taliban take control of Kabul airport, do a symbolic march across runway | World News

4 years ago
EXCLUSIVE: Mohammad Kaif says U19 World Cup-winning team ‘played just like MS Dhoni’ | Cricket News

EXCLUSIVE: Mohammad Kaif says U19 World Cup-winning team ‘played just like MS Dhoni’ | Cricket News

3 years ago
CPI-M Releases Manifesto For Lok Sabha Polls, Promises To Scrap ‘Draconian’ UAPA, PMLA, CAA | India News

CPI-M Releases Manifesto For Lok Sabha Polls, Promises To Scrap ‘Draconian’ UAPA, PMLA, CAA | India News

1 year ago
BREAKING: Britain reports world’s first known Omicron death | World News

BREAKING: Britain reports world’s first known Omicron death | World News

4 years ago

BROWSE BY CATEGORIES

  • Animals
  • Architecture
  • Automobiles
  • Business
  • Culture
  • Fitness
  • International
  • Lifestyle
  • Movies
  • National
  • Sports
  • Technology
  • Travel

BROWSE BY TOPICS

Architecture culture Fitness indian architecture indian culture indian culture and heritage indian news lifestyle national news Technology technology news Travel travelling

About Us

Awaj Ludhiana Ki

Address

2667/3, Kishore Nagar, Tajpur & Jail Road, Ludhiana – 141008

Recent News

  • Nuclear Sites Bombed, IRGC Chief And Top Nuke Scientist Killed In Israeli Strikes On Iran – Details | World News
  • Inevitable War? Israel Has Hit Iran, But What Tehran Knows May Change Everything | World News
  • Ahmedabad Plane Crash: Miracle On Seat 11A; Passenger Survives Fatal Crash With Minor Injuries | India News
  • Ahmedabad Plane Crash: Flight Crashes Into Hostel, Uneaten Food On Tables Shows Haunting Scenes Of Incident | WATCH VIDEO | India News
  • PM Modi-Carney G7 Meeting Opportunity To Explore Pathways To Reset India-Canada Ties: MEA | India News

Category

  • Animals
  • Architecture
  • Automobiles
  • Business
  • Culture
  • Fitness
  • International
  • Lifestyle
  • Movies
  • National
  • Sports
  • Technology
  • Travel

Search

No Result
View All Result

Email

contact@awajludhianaki.org

  • About
  • Advertise
  • Careers

Copyright © 2019 Awaj Ludhiana Ki or it's affiliates | Website by Awaj Ludhiana Ki Team

No Result
View All Result
  • Home
  • Contact us
  • Animals
  • Architecture
  • Automobiles
  • Business
  • Culture
  • Fashion
  • Fitness
  • Food
  • International
  • Lifestyle
  • Movies
  • National
  • Sports
  • Technology
  • Travel
  • Punjab

Copyright © 2019 Awaj Ludhiana Ki or it's affiliates | Website by Awaj Ludhiana Ki Team

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In